SCHEMBL5715447

SCHEMBL5715447

Cc1ncsc1CCN1CCN(C(=O)Oc2ccc(CCSc3nccn3C)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
THRB P10828 2/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
HTR2A P28223 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
HTR7 P34969 1/20 0.38
OPRM1 P35372 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 3/20 0.37
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714447 0.92 SMN1; SMN2 (0.47) SMN1; SMN2THRBRAB9ANPC1HTR2A
SCHEMBL5715270 0.86 THRB (0.47) THRBALDH1A1KMT2AMEN1HTR2A
SCHEMBL5714696 0.86 HTR2A (0.42) SMN1; SMN2THRBMAPK1ALDH1A1KMT2A
SCHEMBL5714485 0.85 NPC1 (0.38) SMN1; SMN2THRBALDH1A1KMT2ARAB9A
SCHEMBL5714007 0.85 CYP3A4 (0.42) SMN1; SMN2THRBALDH1A1KMT2AMEN1
SCHEMBL5714085 0.84 THRB (0.40) SMN1; SMN2THRBMAPK1ALDH1A1KMT2A
SCHEMBL5714580 0.82 MAPT (0.39) SMN1; SMN2THRBALDH1A1KMT2ARAB9A
SCHEMBL5715606 0.82 THRB (0.42) THRBALDH1A1KMT2AALOX15RAB9A
SCHEMBL5714465 0.82 TP53 (0.49) THRBALDH1A1KMT2ARAB9ANPC1
SCHEMBL5714513 0.82 MAPT (0.38) SMN1; SMN2THRBALDH1A1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL SMN1; SMN2 3125/4885THRB 598/4885MAPK1 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.